Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Valneva

DB:AYJ
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AYJ
DB
€232M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Valneva SE, a biotech company, engages in developing and commercializing vaccines for infectious diseases with unmet needs. The last earnings update was 38 days ago. More info.


Add to Portfolio Compare Print
  • Valneva has significant price volatility in the past 3 months.
AYJ Share Price and Events
7 Day Returns
16.2%
DB:AYJ
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-21.2%
DB:AYJ
-13.2%
DE Biotechs
-20.9%
DE Market
AYJ Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Valneva (AYJ) 16.2% -2.4% 6% -21.2% 8.5% -36.3%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • AYJ underperformed the Biotechs industry which returned -13.2% over the past year.
  • AYJ matched the Germany Market (-20.9%) over the past year.
Price Volatility
AYJ
Industry
5yr Volatility vs Market

AYJ Value

 Is Valneva undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Valneva. This is due to cash flow or dividend data being unavailable. The share price is €2.65.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Valneva's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Valneva's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:AYJ PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €-0.02
ENXTPA:VLA Share Price ** ENXTPA (2020-04-03) in EUR €2.56
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Valneva.

DB:AYJ PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:VLA Share Price ÷ EPS (both in EUR)

= 2.56 ÷ -0.02

-127.75x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Valneva is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Valneva is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Valneva's expected growth come at a high price?
Raw Data
DB:AYJ PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -127.75x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
-53.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Valneva, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Valneva's assets?
Raw Data
DB:AYJ PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €1.28
ENXTPA:VLA Share Price * ENXTPA (2020-04-03) in EUR €2.56
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:AYJ PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:VLA Share Price ÷ Book Value per Share (both in EUR)

= 2.56 ÷ 1.28

1.99x

* Primary Listing of Valneva.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Valneva is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Valneva's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Valneva has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

AYJ Future Performance

 How is Valneva expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-53.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Valneva expected to grow at an attractive rate?
  • Unable to compare Valneva's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Valneva's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Valneva's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:AYJ Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:AYJ Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts -53.3%
DB:AYJ Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 6.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:AYJ Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:AYJ Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 156 -85 1
2021-12-31 135 -48 -55 5
2020-12-31 113 -41 -45 5
2020-04-05
DB:AYJ Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 126 6 -2
2019-09-30 116 10 4
2019-06-30 109 16 1
2019-03-31 116 17 7
2018-12-31 113 16 3
2018-09-30 107 6 -7
2018-06-30 110 10 -7
2018-03-31 108 5 -8
2017-12-31 105 13 -11
2017-09-30 103 17 -11
2017-06-30 100 19 -14
2017-03-31 102 25 -46

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Valneva is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Valneva's revenue is expected to grow by 6.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:AYJ Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Valneva Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AYJ Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 -0.94 -0.94 -0.94 1.00
2021-12-31 -0.66 -0.49 -0.97 4.00
2020-12-31 -0.49 -0.43 -0.56 4.00
2020-04-05
DB:AYJ Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 -0.02
2019-09-30 0.05
2019-06-30 0.01
2019-03-31 0.08
2018-12-31 0.04
2018-09-30 -0.09
2018-06-30 -0.09
2018-03-31 -0.11
2017-12-31 -0.15
2017-09-30 -0.13
2017-06-30 -0.19
2017-03-31 -0.59

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Valneva will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Valneva's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Valneva has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

AYJ Past Performance

  How has Valneva performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Valneva's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Valneva does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Valneva's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Valneva's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Valneva's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Valneva Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AYJ Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 126.20 -1.74 42.54
2019-09-30 116.10 4.08 40.32
2019-06-30 108.58 1.06 38.76
2019-03-31 115.81 6.66 38.01
2018-12-31 113.04 3.26 37.86
2018-09-30 107.28 -6.93 37.88
2018-06-30 110.40 -7.31 37.57
2018-03-31 108.25 -8.37 35.14
2017-12-31 105.29 -11.48 33.42
2017-09-30 103.49 -10.52 32.50
2017-06-30 100.36 -14.09 31.97
2017-03-31 102.33 -45.80 32.29
2016-12-31 97.89 -49.18 31.05
2016-09-30 93.39 -62.87 29.21
2016-06-30 95.51 -61.02 27.62
2016-03-31 88.52 -35.45 26.59
2015-12-31 83.33 -20.62 23.52
2015-09-30 73.80 -15.74 19.91
2015-06-30 65.17 -13.14 17.35
2015-03-31 54.84 -9.37 14.95
2014-12-31 42.43 -26.27 14.14
2014-09-30 40.96 -20.64 12.82
2014-06-30 42.79 -28.04 16.97
2014-03-31 41.21 -28.54 16.90
2013-12-31 35.99 -23.97 14.72
2013-09-30 25.76 -21.79 14.32
2013-06-30 12.83 -14.25 8.03

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Valneva has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Valneva has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Valneva improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Valneva's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Valneva has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

AYJ Health

 How is Valneva's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Valneva's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Valneva is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Valneva's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Valneva's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 4.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Valneva Company Filings, last reported 3 months ago.

DB:AYJ Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 135.15 26.32 64.44
2019-09-30 131.63 25.86 67.39
2019-06-30 131.72 14.80 69.94
2019-03-31 139.19 16.34 68.06
2018-12-31 143.19 30.94 81.73
2018-09-30 89.73 60.35 33.07
2018-06-30 91.94 61.99 37.72
2018-03-31 94.72 66.52 36.17
2017-12-31 92.67 43.98 38.06
2017-09-30 96.21 69.91 40.56
2017-06-30 98.14 74.08 43.91
2017-03-31 99.46 75.35 41.52
2016-12-31 100.05 54.13 42.18
2016-09-30 97.58 80.20 39.65
2016-06-30 104.27 80.47 38.02
2016-03-31 139.77 82.43 32.78
2015-12-31 144.34 73.04 41.91
2015-09-30 145.21 87.99 34.62
2015-06-30 150.97 89.25 41.04
2015-03-31 158.44 90.85 38.33
2014-12-31 124.44 43.10 28.88
2014-09-30 136.91 71.55 36.35
2014-06-30 140.91 70.59 36.74
2014-03-31 137.22 71.32 28.20
2013-12-31 144.11 40.25 40.17
2013-09-30 150.95 51.59 18.18
2013-06-30 121.21 79.40 23.11
  • Valneva's level of debt (19.5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (34.7% vs 19.5% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Valneva has sufficient cash runway for more than 3 years based on current free cash flow.
  • Valneva has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of -48.6% each year.
X
Financial health checks
We assess Valneva's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Valneva has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

AYJ Dividends

 What is Valneva's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Valneva dividends.
If you bought €2,000 of Valneva shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Valneva's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Valneva's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:AYJ Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:AYJ Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31
2020-04-05

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Valneva has not reported any payouts.
  • Unable to verify if Valneva's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Valneva's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Valneva has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Valneva's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Valneva afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Valneva has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

AYJ Management

 What is the CEO of Valneva's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Thomas Lingelbach
COMPENSATION €648,797
AGE 56
TENURE AS CEO 6.9 years
CEO Bio

Mr. Thomas Lingelbach has been the Chief Executive Officer of Valneva SE since May 2013 and as its Chairman and Member of the Management Board since May 10, 2013. Mr. Lingelbach serves as a Managing Director of Valneva Scotland Ltd. Mr. Lingelbach has been Co-President of Valneva SE since July 17, 2017 and served as its President since May 2013 until July 17, 2017. He served as Chairman of the Management Board of Intercell Ag and served as its Chief Executive Officer since May 10, 2011. He served as the Managing Director of Intercell Ag. since August 3, 2006. He serves as the President of Valneva USA, Inc. since 2008. He has a long international pharmaceutical management track-record and extensive knowledge and expertise in the field of development, industrialization and commercialization of vaccines. He served as the Chief Executive Officer of Valneva USA, Inc. He joined Intercell in 2006. He served as the Chief Operating Officer of Intercell Biomedical Research & Development AG (Intercell) since August 3, 2006 and served as its Member of the Management Board since November 2007. He has more than twenty years of experience in the phar-ma and vaccines industry, having held a variety of leading positions of increasing interna-tional responsibility at Hoechst AG from 1989 to 1993, Behringwerke AG (1993-1997), Chiron Vaccines (1997-2005), and Novartis Vaccines and Diagnostics (2005-2006), Mr. Lingelbach has been significantly involved in Novartis' Vaccines and Diagnostics integration activities acting as General Manager and Managing Director of its German Vaccines Operations. Since 2001 until Chiron's acquisition by Novartis in April 2006, he served as a Vice President Industrial Operations in Chiron Vaccines' Executive Committee from 2003 to 2006 and as well as Managing Director of Chiron-Behring GmbH & Co. KG in Germany from 2001 to 2006. He has been a Director of Valneva USA, Inc. since 2008. Mr. Lingelbach holds a Master's Degree in Engineering and complemented his Education with a Business Administration program from 1999 to 2000 with a Business Administration program.

CEO Compensation
  • Thomas's compensation has increased whilst company is loss making.
  • Thomas's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Valneva management team in years:

2.8
Average Tenure
56
Average Age
  • The tenure for the Valneva management team is about average.
Management Team

Thomas Lingelbach

TITLE
Chairman of the Management Board
COMPENSATION
€649K
AGE
56
TENURE
6.9 yrs

Franck Grimaud

TITLE
President
COMPENSATION
€415K
AGE
52
TENURE
2.8 yrs

David Lawrence

TITLE
CFO & Member of Management Board
COMPENSATION
€467K
AGE
56
TENURE
2.7 yrs

Frédéric Jacotot

TITLE
General Counsel
COMPENSATION
€226K
AGE
55
TENURE
3 yrs

Wolfgang Bender

TITLE
Chief Medical Officer & Member of Management Board
COMPENSATION
€469K
AGE
65
TENURE
2.6 yrs

Laetitia Bachelot-Fontaine

TITLE
Head of Investor Relations & Corporate Communications

Gerald Strohmaier

TITLE
Human Resources Officer

Kerstin Westritschnig

TITLE
Head of Clinical Development

Janet Hoogstraate

TITLE
Chairman of the Management Board of Valneva Sweden AB

Christian Taucher

TITLE
Head of Global Medical Affairs
Board of Directors Tenure

Average tenure and age of the Valneva board of directors in years:

0.8
Average Tenure
66
Average Age
  • The average tenure for the Valneva board of directors is less than 3 years, this suggests a new board.
Board of Directors

Frédéric Grimaud

TITLE
Chairman of Supervisory Board
COMPENSATION
€50K
AGE
54

Lisa Shaw-Marotto

TITLE
Vice Chairperson of Supervisory Board
COMPENSATION
€30K
AGE
51
TENURE
0.8 yrs

Jim Sulat

TITLE
Member of Supervisory Board
COMPENSATION
€45K
AGE
69
TENURE
7.1 yrs

Ralf Clemens

TITLE
Chair of Scientific Advisory Board
COMPENSATION
€35K
AGE
66
TENURE
0.8 yrs

Alain Munoz

TITLE
Member of Scientific Advisory Board
COMPENSATION
€35K
AGE
70
TENURE
0.8 yrs

Alexander Von Gabain

TITLE
Independent Member of Supervisory Board
COMPENSATION
€30K
AGE
69
TENURE
7.1 yrs

Anne-Marie Graffin

TITLE
Member of Supervisory Board
COMPENSATION
€30K
AGE
58
TENURE
7.1 yrs

Sandra Poole

TITLE
Member of Supervisory Board
COMPENSATION
€13K
AGE
55
TENURE
2.8 yrs

Norman Baylor

TITLE
Member of Scientific Advisory Board
TENURE
0.4 yrs

George Siber

TITLE
Member of Scientific Advisory Board
AGE
74
TENURE
0.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Valneva's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Valneva has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

AYJ News

Simply Wall St News

AYJ Company Info

Description

Valneva SE, a biotech company, engages in developing and commercializing vaccines for infectious diseases with unmet needs. Its portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT indicated for the prevention of Japanese encephalitis; and DUKORAL indicated for the prevention of cholera and in some countries prevention of diarrhea caused by ETEC. The company has various vaccines in development, including a vaccine against Lyme disease. It has operations in Austria, Sweden, the United Kingdom, France, Canada, and the United States. Valneva SE is based in Nantes, France.

Details
Name: Valneva SE
AYJ
Exchange: DB
Founded:
€232,309,026
90,923,298
Website: http://www.valneva.com
Address: Valneva SE
Campus Bio-Ouest,
6, Rue Alain Bombard,
Nantes,
Pays de la Loire, 44800,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA VLA Common Shares Euronext Paris FR EUR 29. Jun 2007
OTCPK INRL.F Common Shares Pink Sheets LLC US USD 29. Jun 2007
DB AYJ Common Shares Deutsche Boerse AG DE EUR 29. Jun 2007
XTRA AYJ Common Shares XETRA Trading Platform DE EUR 29. Jun 2007
LSE 0OB3 Common Shares London Stock Exchange GB EUR 29. Jun 2007
SWX VLA Common Shares SIX Swiss Exchange CH CHF 29. Jun 2007
WBAG VLA Common Shares Wiener Boerse AG AT EUR 29. Jun 2007
ENXTPA VLAP PRF SHS EUR0.01 Euronext Paris FR EUR 28. May 2013
OTCPK VNVL.F PRF SHS EUR0.01 Pink Sheets LLC US USD 28. May 2013
LSE 0QS6 PRF SHS EUR0.01 London Stock Exchange GB EUR 28. May 2013
Number of employees
Current staff
Staff numbers
480
Valneva employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 21:11
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/31
Last earnings filing: 2020/02/27
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.